Pfizer Shares Drop 2.49% as FDA Grants Priority Review to Brepocitinib, $1.1B Volume Ranks 125th

Market Snapshot

On March 3, 2026, Pfizer (PFE) shares declined by 2.49%, closing at $26.58. The stock traded with a volume of $1.10 billion, ranking 125th in daily trading activity. Despite the FDA’s recent priority review designation for Priovant Therapeutics’ brepocitinib—a key asset backed by Pfizer—the stock underperformed relative to broader market benchmarks. The decline occurred amid mixed investor sentiment, balancing optimism over regulatory progress for brepocitinib with broader market volatility.

Key Drivers

The primary catalyst for Pfizer’s stock movement was the FDA’s acceptance of Priovant Therapeutics’ New Drug Application (NDA) for brepocitinib, a dual inhibitor of TYK2 and JAK1, for the treatment of dermatomyositis (DM). The FDA granted the application Priority Review, assigning a Prescription Drug User Fee Act (PDUFA) target action date in Q3 2026. If approved, brepocitinib would become the first FDA-approved targeted therapy for DM, a rare autoimmune disease with limited treatment options. The Phase 3 VALOR trial, which enrolled 241 patients, demonstrated statistically significant improvements in clinical endpoints, including the myositis Total Improvement Score (TIS) and steroid reduction. Over two-thirds of patients receiving the 30 mg dose achieved a TIS40 threshold, a metric twice the minimum clinically important difference.

However, the stock’s decline suggests market skepticism or caution. While the FDA’s Priority Review is a positive step, investors may have priced in the news ahead of the announcement or remained wary of potential regulatory hurdles. The trial also noted increased serious infections in the 30 mg brepocitinib arm compared to placebo, though most resolved with medical management. Additionally, the drug’s safety profile, while comparable to existing JAK and TYK2 inhibitors, may raise concerns about long-term side effects. These factors could have tempered enthusiasm, particularly given the drug’s intended use for a niche patient population.

Another layer of complexity lies in the broader competitive landscape. Priovant’s partnership with Roivant Sciences, a key stakeholder in brepocitinib’s development, highlights the collaborative nature of its pipeline. However, the drug’s success hinges on securing reimbursement and physician adoption, particularly in a market where corticosteroids and broader immunosuppressants remain first-line treatments. The Phase 3 data, while robust, must translate into real-world efficacy and safety to justify its potential as a first-in-class therapy.

The settlement between Genevant Sciences and Moderna, a subsidiary of Roivant, further underscores the legal and financial dynamics at play. While this $2.25 billion agreement does not directly impact brepocitinib, it reflects the high-stakes environment of nucleic acid delivery technologies, a field where Pfizer has significant exposure through its partnerships and internal R&D. Investors may be recalibrating expectations for Roivant’s broader portfolio, indirectly affecting Pfizer’s stock as a co-backer of Priovant.

Finally, Pfizer’s stock performance must be contextualized within its broader business. The company’s diversified portfolio, including vaccines, oncology drugs, and rare disease therapies, provides a buffer against short-term volatility. However, brepocitinib represents a high-impact asset for Priovant, and its approval could significantly enhance Pfizer’s revenue streams in autoimmune diseases. The market’s muted reaction on March 3 may indicate that the long-term potential of brepocitinib is already partially priced in, with investors awaiting clearer signals from the FDA’s Q3 decision.

In summary, while the FDA’s Priority Review for brepocitinib is a milestone for Priovant and by extension Pfizer, the stock’s 2.49% decline reflects a balance of optimism and caution. Key uncertainties include the FDA’s final decision, real-world adoption rates, and the drug’s ability to differentiate itself in a competitive therapeutic landscape. Investors will closely monitor the Q3 2026 timeline and subsequent commercialization efforts to assess the full impact of this regulatory progress.